Enzastaurin - CAS 170364-57-5
Catalog number:
170364-57-5
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
PKC
Description:
Enzastaurin HCL is the hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity. Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden.
Publictions citing BOC Sciences Products
  • >> More
Synonyms:
Enzastaurin HCl; Enzastaurin Hydrochloride; LY317615; LY-317615; D04014; LY 317615.
MSDS:
Inquire
Current Developer:
Eli Lilly Inc
1.A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.
Odia Y1, Iwamoto FM2, Moustakas A3, Fraum TJ4, Salgado CA5, Li A6, Kreisl TN2, Sul J7, Butman JA8, Fine HA9. J Neurooncol. 2016 Mar;127(1):127-35. doi: 10.1007/s11060-015-2020-x. Epub 2015 Dec 7.
We evaluated the efficacy of combination enzastaurin (LY317615) and bevacizumab for recurrent malignant gliomas and explored serologic correlates. We enrolled 81 patients with glioblastomas (GBM, n = 40) and anaplastic gliomas (AG, n = 41). Patients received enzastaurin as a loading dose of 1125 mg, followed by 500 or 875 mg daily for patients on non-enzyme-inducing or enzyme-inducing antiepileptics, respectively. Patients received bevacizumab 10 mg/kg intravenously biweekly. Clinical evaluations were repeated every 4 weeks. Magnetic resonance imaging was obtained at baseline and every 8 weeks from treatment onset. Phosphorylated glycogen synthase kinase (GSK)-3 levels from peripheral blood mononuclear cells (PBMCs) were checked with each MRI. Median overall survival was 7.5 and 12.4 months for glioblastomas and anaplastic glioma cohorts, with median progression-free survivals of 2.0 and 4.4 months, respectively. Of GBM patients, 3/40 (7.
2.A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome.
Doyle JJ1,2, Doyle AJ1,3, Wilson NK1, Habashi JP1,4, Bedja D5,6, Whitworth RE7, Lindsay ME8, Schoenhoff F9,10, Myers L1, Huso N1, Bachir S1, Squires O1, Rusholme B1, Ehsan H2, Huso D11, Thomas CJ12, Caulfield MJ3, Van Eyk JE10, Judge DP13, Dietz HC1,4,13; Elife. 2015 Oct 27;4. pii: e08648. doi: 10.7554/eLife.08648.
Calcium channel blockers (CCBs) are prescribed to patients with Marfan syndrome for prophylaxis against aortic aneurysm progression, despite limited evidence for their efficacy and safety in the disorder. Unexpectedly, Marfan mice treated with CCBs show accelerated aneurysm expansion, rupture, and premature lethality. This effect is both extracellular signal-regulated kinase (ERK1/2) dependent and angiotensin-II type 1 receptor (AT1R) dependent. We have identified protein kinase C beta (PKCβ) as a critical mediator of this pathway and demonstrate that the PKCβ inhibitor enzastaurin, and the clinically available anti-hypertensive agent hydralazine, both normalize aortic growth in Marfan mice, in association with reduced PKCβ and ERK1/2 activation. Furthermore, patients with Marfan syndrome and other forms of inherited thoracic aortic aneurysm taking CCBs display increased risk of aortic dissection and need for aortic surgery, compared to patients on other antihypertensive agents.
3.PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux.
Zestos AG1,2, Mikelman SR1, Kennedy RT1,2, Gnegy ME1. ACS Chem Neurosci. 2016 Mar 28. [Epub ahead of print]
Amphetamine abuse afflicts over 13 million people, and there is currently no universally accepted treatment for amphetamine addiction. Amphetamine serves as a substrate for the dopamine transporter and reverses the transporter to cause an increase in extracellular dopamine. Activation of the beta subunit of protein kinase C (PKCβ) enhances extracellular dopamine in the presence of amphetamine by facilitating the reverse transport of dopamine and internalizing the D2 autoreceptor. We previously demonstrated that PKCβ inhibitors block amphetamine-stimulated dopamine efflux in synaptosomes from rat striatum in vitro. In this study, we utilized in vivo microdialysis in live, behaving rats to assess the effect of the PKCβ inhibitors, enzastaurin and ruboxistaurin, on amphetamine-stimulated locomotion and increases in monoamines and their metabolites. A 30 min perfusion of the nucleus accumbens core with 1 μM enzastaurin or 1 μM ruboxistaurin reduced efflux of dopamine and its metabolite 3-methoxytyramine induced by amphetamine by approximately 50%.
4.Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCε/δ-induced ERK pathways.
Chauvin L1, Goupille C2, Blanc C1, Pinault M1, Domingo I1, Guimaraes C1, Bougnoux P2, Chevalier S3, Mahéo K4. Biochim Biophys Acta. 2016 Apr;1864(4):380-90. doi: 10.1016/j.bbalip.2016.01.012. Epub 2016 Jan 26.
Taxanes can induce drug resistance by increasing signaling pathways such as PI3K/Akt and ERK, which promote survival and cell growth in human cancer cells. We have previously shown that long chain n-3 polyunsaturated fatty acids, such as docosahexaenoic acid (DHA, 22:6n-3) decrease resistance of experimental mammary tumors to anticancer drugs. Our objective was to determine whether DHA could increase tumor sensitivity to docetaxel by down-regulating these survival pathways. In docetaxel-treated MDA-MB-231 cells, phosphorylated-ERK1/2 levels were increased by 60% in membrane and nuclear compartments, compared to untreated cells. Our data showed that ERK1/2 activation depended on PKC activation since: i) enzastaurin (a pan-PKC inhibitor) blocked docetaxel-induced ERK1/2 phosphorylation ii) docetaxel increased PKC activity by 30% and phosphatidic acid level by 1.6-fold iii) inhibition of PKCε and PKCδ by siRNA resulted in reduced phosphorylated ERK1/2 levels.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PKC Products


CAS 60857-08-1 Prostratin

Prostratin
(CAS: 60857-08-1)

Prostratin is an activator of protein kinase C (PKC) and also an activator of nuclear factor KB (NF-KB) mediated through activation of the IKKs (IKB kinases). I...

CAS 37558-16-0 Phorbol 12,13-dibutyrate

Phorbol 12,13-dibutyrate
(CAS: 37558-16-0)

Phorbol 12,13-dibutyrate, a protein kinase C activator, stimulates the phosphorylation of Na+,K+- ATPase, thereby inhibiting its activity.

CAS 133053-19-7 Go6983

Go6983
(CAS: 133053-19-7)

GO6983 is a potent protein kinase C (PKC) inhibitor. GO6893 displays cardioprotective properties; reduces polymorphonuclear leukocyte adherence and infiltration...

PKC-IN-1
(CAS: 1046787-18-1)

PKC-IN-1 has been found to be a PKCβII inhibitor that probably has biological activity in antineoplastic studies. Ki: 14.9 nM.

CAS 17673-25-5 Phorbol

Phorbol
(CAS: 17673-25-5)

Phorbol, derived from the roots of Euphorbia pekinensis Rupr., as a tumor promoter it is able to activate protein kinase C.

NSC305787 hydrochloride
(CAS: 53868-26-1)

NSC305787 hydrochloride is a small molecule inhibitor of PKC (IC50=8.3 μM) that directly inhibits ezrin protein as an approach to prevent tumor metastasis.

CAS 169939-94-0 Ruboxistaurin

Ruboxistaurin
(CAS: 169939-94-0)

Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-m...

CAS 30220-46-3 Ingenol

Ingenol
(CAS: 30220-46-3)

Ingenol, the analogue of Ingenol 3-Angelate found in the seeds of Euphorbia lathyris L, is an extremely weak PKC (protein kinase C) activator ( Ki=30 μM, ED50=2...

CAS 138489-18-6 Ro 31-8220 Mesylate

Ro 31-8220 Mesylate
(CAS: 138489-18-6)

Ro 31-8220 inhibits rat brain PKC activity with IC50 of 23 nM, and does not show any high degree of selectivity between PKC-α, PKC-β, PKC-γ, and PKC-ε.

CAS 165800-06-6 Zoledronic acid monohydrate

Zoledronic acid monohydrate
(CAS: 165800-06-6)

Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inh...

CAS 83314-01-6 Bryostatin 1

Bryostatin 1
(CAS: 83314-01-6)

Bryostatin 1, a structurally unique macrolactone marine natural product, is a protein kinase C (PKC) activator that binds with high affinity (Ki = 1.35 nM). Bry...

CAS 164658-13-3 CGP60474

CGP60474
(CAS: 164658-13-3)

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics rela...

CAS 62996-74-1 Staurosporine

Staurosporine
(CAS: 62996-74-1)

Staurosporine is broad spectrum protein kinase inhibitor. Enzymes inhibited include protein kinase C (IC50 = 3 nM), protein kinase A (IC50 = 7 nM), p60v-src tyr...

CAS 170364-57-5 Enzastaurin

Enzastaurin
(CAS: 170364-57-5)

Enzastaurin HCL is the hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity. Binding to the ATP-...

CAS 163751-35-7 rac-3-Hexadecanamido-2-methoxypropan-1-ol Phosphocholine Monohydrate

rac-3-Hexadecanamido-2-methoxypropan-1-o
(CAS: 163751-35-7)

The Pharmacological activity of this molecular is Growth Inhibition of Malignant Cells in vivo and in vitro and cytotoxic properties may result inhibition of pr...

CAS 425637-18-9 Sotrastaurin

Sotrastaurin
(CAS: 425637-18-9)

Sotrastaurin, also known as AEB-701, is an orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities....

CAS 87745-28-6 Bryostatin 2

Bryostatin 2
(CAS: 87745-28-6)

Bryostatin 2, an analog of Bryostatin 1, is an activator of PKC (protein kinase C) with anti-tumor properties. Bryostatin 2 inhibits DNA synthesis at 100 nM in ...

CAS 90365-57-4 (-)-Indolactam V

(-)-Indolactam V
(CAS: 90365-57-4)

(-)-Indolactam V is an indole alkaloid compound which activates protein kinase C (PKC), which strongly directs human ES cell-derived definitive endoderm into pa...

CAS 75567-37-2 Ingenol Mebutate

Ingenol Mebutate
(CAS: 75567-37-2)

Ingenol Mebutate is a substance found in the sap of the plant Euphorbia peplus and an inducer of cell death. It is effective for field treatment of actinic kera...

CAS 1874276-76-2 LXS196

LXS196
(CAS: 1874276-76-2)

LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under clinical trials for the treatment of uveal melanoma, the most common cancer of the e...

Chemical Structure

CAS 170364-57-5 Enzastaurin

Quick Inquiry

Verification code

Featured Items